Table 2 Monoclonal antibodies under development
Monoclonal antibody | Development status | Route of administration | In vivo efficacy in animal models (model organism) | Protection |
|---|---|---|---|---|
mAb 51168 | Pre-clinical | Intraperitoneal | protected 100% of AG129 mice against challenge. | all EV-A71 subgenogroups |
mAb 53168 | Pre-clinical | Intraperitoneal | all subgenogroups except for B5. | |
CT11F9163 | Pre-clinical | Intraperitoneal | Protected 100% of BALB/c mice against lethal EV-A71 infection. | Neutralization of EV-A71 subgenogroup A, B3-5, C2, C4 and C5 in vitro |
BB145 IgG2a79 | Pre-clinical | Intraperitoneal | Protected 100% of BALB/c mice against EV-A71 morbidity and mortality. | Neutralization of EV-A71 subgenogroups A, B3-5, C2, C4-5, CVA16 |
mAb 10D317 | Pre-clinical | Intraperitoneal | Protected 100% of AG129 mice against lethal EV-A71 infection. | 100% effective against all EV-A71 subgenogroups |
3A12162 | Pre-clinical | Intraperitoneal | Protected 38.9% of ICR mice against lethal EV-A71 infection. | 100% effective against EV-A71 subgenogroups |
3A10162 | Pre-clinical | Intraperitoneal | Protected 27.3% of ICR mice against lethal EV-A71 infection. | 100% effective against EV-A71 subgenogroups |
Bs(scFv)4-IgG-1164 | Pre-clinical | Intraperitoneal | Protected 100% of AG129 mice against lethal EV-A71 infection. | Neutralization of EV-A71 subgenogroups B3, B5, C2, C4, and C5 |
h1A6.2161 | Pre-clinical | Intraperitoneal | Protected 100% of neonatal BALB/c mice against lethal EV-A71 infection. | Neutralization of EV-A71 subgenogroups B4, C2, and C4 |
Pre-clinical | NA | Protected 100% of neonatal ICR mice against lethal EV-A71, CVA6, CVA10, and CVA16 infection. | Neutralization of EV-A71 subgenogroups C4, CVA6, CVA10, and CVA16 | |
22 and 24165 | Pre-clinical | NA | NA | Binding to EV-A71 subgenogroups B5, C2, and C4 |
JL2166 | Pre-clinical | NA | NA | Neutralization of EV-A71 subgenogroups C4 |
